CareDx Announces Fourth Quarter and Full Year 2025 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue of $108 million, an increase of 25% year-over-year Testing servic.

Business Wire • 6 hours ago

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective.

Business Wire • 4 hours ago

CareDx (CDNA) Q4 Earnings Miss Estimates

CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago.

Zacks Investment Research • an hour ago

CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • 40 minutes ago

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026. About CareDx CareDx is a precision medicine company de.

Business Wire • Feb 18, 2026

CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT

CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell therapy markets.

Zacks Investment Research • Feb 16, 2026

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

Seeking Alpha • Feb 15, 2026

CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript

CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript

Seeking Alpha • Feb 12, 2026

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced pivotal clinical validation results of AlloHeme™, a non-invasive, next‑generation sequencing (NGS)–based, and artificial intelligence (AI)-powered monitoring test designed to predict relapse in.

Business Wire • Feb 12, 2026

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30.

Business Wire • Feb 10, 2026